Table 2.

In Vivo pharmakokinetic parameters of inhibitors in female Sprague-Dawley rats (n = 3, mean ± SD) following a single intravenous (i.v.) and oral (p.o.) administration

Compound	i.v. PK parametersa			p.o. PK parametersb
	AUC0-inf (μg.min.mL–1)	CL (mL.min–1.kg–1)	t1/2 (min)	Cmax (μg.mL–1)	AUC0-inf (μg.min.mL–1)	F (%)
10c	519 ± 115	4.9 ± 0.9	11.2 ± 2.2	0.40 ± 0.20	66 ± 41	1.3 ± 0.7
11c	304 ± 60	8.4 ± 1.9	10.6 ± 0.7	0.70 ± 0.07	100 ± 14	3.5 ± 0.2
	1040 ± 330	2.5 ± 0.9	32.5 ± 7.4	0.46 ± 0.30	187 ± 11	1.8 ± 0.9
	913 ± 65	2.7 ± 0.2	31.7 ± 1.9	1.09 ± 0.03	422 ± 70	4.7 ± 1.1
	366 ± 33	6.9 ± 0.3	17.4 ± 1.4	0.64 ± 0.22	84 ± 12	2.3 ± 0.4
	807 ± 78	3.1 ± 0.3	37.0 ± 1.7	0.92 ± 0.04	266 ± 2	3.5 ± 0.2
	312 ± 54	8.5 ± 1.6	17.2 ± 1.3	0.97 ± 0.42	362 ± 85	11.4 ± 0.3
	10100 ± 2200	0.24 ± 0.06	267 ± 36	5.99 ± 0.56	4730 ± 540	5.3 ± 1.3

^ai.v. dose (D_i.v.) = 2.5 mg/kg

^bp.o. dose (D_p.o.) = 25 mg/kg

^creference 34.

AUC_0-inf: area under the plasma concentration-time curve from time 0 to infinity, CL: clearance, t_1/2: terminal elimination half-life, C_max: maximum plasma concentration, F: relative oral bioavailability calculated as follows F = 100 × [(AUC_p.o. × D_i.v.)/(AUC_i.v. × D_p.o.)].